Litcius/Paper detail

95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma

Milind Javle, Lionel Aurelien Kankeu Fonkoua, Amit Mahipal, C-Y. Liao, Christos Fountzilas, D. Li, Meredith S. Pelster, Sanjay Goel, P. Peng, Caixia Sun, Hui Wang, Kristen Hennessy, Xueyao Fu, L. Neo, Y. Shan, Ping Huang, Dong Wu, Frank Wu, Jean Fan, Sarina A. Piha‐Paul

2023Annals of Oncology12 citationsDOIOpen Access PDF

Topics & Concepts

Fibroblast growth factor receptorMedicineRefractory (planetary science)Fibroblast growth factorCancer researchOncologyInternal medicineReceptorAstrobiologyPhysicsCholangiocarcinoma and Gallbladder Cancer StudiesFibroblast Growth Factor ResearchMetastasis and carcinoma case studies
95MO Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma | Litcius